Literature DB >> 20522642

Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion.

Omer Nuri Pamuk1, Peter H Lapchak, Poonam Rani, Polly Pine, Jurandir J Dalle Lucca, George C Tsokos.   

Abstract

Reperfusion injury to tissue following an ischemic event occurs as a consequence of an acute inflammatory response that can cause significant morbidity and mortality. Components of both the innate (complement, immunoglobulin, monocytes, and neutrophils) and adaptive (B and T lymphocytes) immune systems have been demonstrated to mediate tissue injury. Spleen tyrosine kinase (Syk) is responsible for membrane-mediated signaling in various cell types including B lymphocytes, macrophages, and T cells. We investigated the ability of a small drug Syk inhibitor, R788, to protect mice against mesenteric ischemia-reperfusion (I/R)-induced local (intestine) and remote lung injury. Mice were fed with chow containing a Syk inhibitor for 6 days before the performance of intestinal I/R, which resulted in silencing of the expression of the active phosphorylated Syk. Syk inhibition significantly suppressed both local and remote lung injury. The beneficial effect was associated with reduced IgM and complement 3 deposition in the tissues and significant reduction of polymorphonuclear cell infiltration. Our data place Syk upstream of events leading to the binding of natural antibodies to the ischemia-conditioned tissues and urge the consideration of the use of Syk inhibitors in the prevention or improvement of tissue injury of organs exposed to ischemia or hypoperfusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20522642      PMCID: PMC3774480          DOI: 10.1152/ajpgi.00198.2010

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  34 in total

1.  C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusion.

Authors:  Sherry D Fleming; Jimie Anderson; Felisa Wilson; Terez Shea-Donohue; George C Tsokos
Journal:  Clin Immunol       Date:  2003-01       Impact factor: 3.969

2.  Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury.

Authors:  Ming Zhang; William G Austen; Isaac Chiu; Elisabeth M Alicot; Rachel Hung; Minghe Ma; Nicola Verna; Min Xu; Herbert B Hechtman; Francis D Moore; Michael C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

3.  Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal.

Authors:  C J Chiu; A H McArdle; R Brown; H J Scott; F N Gurd
Journal:  Arch Surg       Date:  1970-10

4.  An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.

Authors:  K R Cooke; L Kobzik; T R Martin; J Brewer; J Delmonte; J M Crawford; J L Ferrara
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

Review 5.  Reactive species mechanisms of cellular hypoxia-reoxygenation injury.

Authors:  Chuanyu Li; Robert M Jackson
Journal:  Am J Physiol Cell Physiol       Date:  2002-02       Impact factor: 4.249

6.  Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.

Authors:  Guo-Min Deng; Lena Liu; Frances Rena Bahjat; Polly R Pine; George C Tsokos
Journal:  Arthritis Rheum       Date:  2010-07

7.  Priming of neutrophils with tumor necrosis factor-alpha measured as Fc gamma receptor-mediated respiratory burst correlates with increased complement receptor 3 membrane density.

Authors:  B Asman; A Gustafsson; K Bergström
Journal:  Int J Clin Lab Res       Date:  1996

8.  Intestinal reperfusion injury is mediated by IgM and complement.

Authors:  J P Williams; T T Pechet; M R Weiser; R Reid; L Kobzik; F D Moore; M C Carroll; H B Hechtman
Journal:  J Appl Physiol (1985)       Date:  1999-03

9.  Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire.

Authors:  Sherry D Fleming; Terez Shea-Donohue; Joel M Guthridge; Liudmila Kulik; Thomas J Waldschmidt; Matthew G Gipson; George C Tsokos; V Michael Holers
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

10.  Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury.

Authors:  Georg Karpel-Massler; Sherry D Fleming; Michael Kirschfink; George C Tsokos
Journal:  J Surg Res       Date:  2003-12       Impact factor: 2.192

View more
  20 in total

1.  A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.

Authors:  Valerie Cuvier; Ulrike Lorch; Stephan Witte; Aurelie Olivier; Sebastien Gibot; Isabelle Delor; Jean-Jacques Garaud; Marc Derive; Margarita Salcedo-Magguilli
Journal:  Br J Clin Pharmacol       Date:  2018-07-20       Impact factor: 4.335

2.  Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases.

Authors:  Marc Derive; Frédéric Massin; Sébastien Gibot
Journal:  Self Nonself       Date:  2010-07-02

3.  IL-17A Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion Injury.

Authors:  Mayya Geha; Maria G Tsokos; Robin E Bosse; Tatyana Sannikova; Yoichiro Iwakura; Jurandir J Dalle Lucca; Rene De Waal Malefyt; George C Tsokos
Journal:  J Immunol       Date:  2017-09-06       Impact factor: 5.422

4.  The role of Syk kinase in ultraviolet-mediated skin damage.

Authors:  E Papazoglou; Z Y Huang; C Sunkari; J Uitto
Journal:  Br J Dermatol       Date:  2011-05-30       Impact factor: 9.302

5.  Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.

Authors:  Terence N Bukong; Arvin Iracheta-Vellve; Banishree Saha; Aditya Ambade; Abhishek Satishchandran; Benedek Gyongyosi; Patrick Lowe; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2016-07-22       Impact factor: 17.425

6.  Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats.

Authors:  Yue He; Liang Xu; Bo Li; Zhen-Ni Guo; Qin Hu; Zongduo Guo; Junjia Tang; Yujie Chen; Yang Zhang; Jiping Tang; John H Zhang
Journal:  Stroke       Date:  2015-07-02       Impact factor: 7.914

Review 7.  Getting Syk: spleen tyrosine kinase as a therapeutic target.

Authors:  Robert L Geahlen
Journal:  Trends Pharmacol Sci       Date:  2014-06-26       Impact factor: 14.819

8.  Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.

Authors:  Stephen P McAdoo; Gurjeet Bhangal; Theresa Page; H Terence Cook; Charles D Pusey; Frederick W K Tam
Journal:  Kidney Int       Date:  2015-02-25       Impact factor: 10.612

Review 9.  Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.

Authors:  Omer N Pamuk; George C Tsokos
Journal:  Arthritis Res Ther       Date:  2010-12-17       Impact factor: 5.156

10.  Fostamatinib Disodium.

Authors:  Stephen P McAdoo; Frederick W K Tam
Journal:  Drugs Future       Date:  2011       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.